Illustration: Axios Visuals
Alkermes boosted its offer Wednesday for Avadel Pharmaceuticals to $2.37 billion, following an unsolicited bid for the biotech from H. Lundbeck last week.
Why it matters: It's the second biopharma bidding war to break out, following Pfizer and Novo Nordisk's battle for obesity startup Metsera.
